Human IL‑13 Biotinylated Antibody (Catalog #
Recombinant Human IL-13 Protein (Catalog #
Measured by its ability to neutralize IL‑13-induced proliferation in the TF‑1 human erythroleukemic cell line. Kitamura, T. et al. (1989) J. Cell Physiol. 140:323. The Neutralization Dose (ND50) is typically 0.15-0.75 ug/mL in the presence of 10 ng/mL Recombinant Human IL‑13.
Please Note: Optimal dilutions should be determined by each laboratory for each application.
are available in the Technical Information section on our website.
Detection of IL‑13 in Human PBMCs by Flow Cytometry.
Human peripheral blood mononuclear cells (PBMCs) treated with 5 ng/mL Recombinant Human IL‑4 (Catalog # 204-IL) and 10 µg/mL Goat Anti-Human IFN‑ gamma Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-285-NA) for 3 days were stained with Mouse Anti-Human IL‑13 Monoclonal Antibody (Catalog # MAB213) followed by Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B) and Mouse Anti-Human CD4 PE-conjugated Monoclonal Antibody (Catalog # FAB3791P). Quadrant markers were set based on control antibody staining (Catalog # MAB002).
Cell Proliferation Induced by IL‑13 and Neutralization by Human IL‑13 Antibody.
Recombinant Human IL‑13 (Catalog # 213-ILB) stimulates proliferation in the TF‑1 human erythroleukemic cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human IL‑13 (10 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human IL‑13 Monoclonal Antibody (Catalog # MAB213). The ND50 is typically 0.15‑0.75 µg/mL.
Preparation and Storage
Reconstitute at 0.5 mg/mL in sterile PBS.
Reconstitution Buffer Available
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
IL-13 is a 17 kDa immunoregulatory cytokine that plays a key role in the pathogenesis of allergic asthma and atopy. It is secreted by Th1 and Th2 CD4+ T cells, NK cells, visceral smooth muscle cells, eosinophils, mast cells, and basophils (1-3). IL-13 circulates as a monomer with two internal disulfide bonds that contribute to a bundled four alpha -helix configuration (4, 5). Mature human IL-13 shares 57%, 59%, and 94% amino acid sequence identity with mouse, rat, and rhesus IL-13, respectively. Despite the low homology, it exhibits cross-species activity between human, mouse, and rat (6, 7). IL-13 has diverse activities on numerous cell types (8). On macrophages, IL-13 suppresses the production of proinflammatory cytokines and other cytotoxic substances. On B cells, IL-13 induces immunoglobulin class switching to IgE, upregulates the expression of MHC class II, CD71, CD72, and CD23, and costimulates proliferation. IL-13 upregulates IL-6 while downregulating IL-1 and TNF-alpha production by fibroblasts and endothelial cells. IL-13 binds with low affinity to IL-13 R alpha 1, triggering IL-13 R alpha 1 association with IL-4 R alpha. This high affinity receptor complex also functions as the type 2 IL-4 receptor complex (9, 10). Additionally, IL-13 binds with high affinity to IL-13 R alpha 2 which is expressed intracellularly, on the cell surface, and as a soluble molecule (11-14). IL-13 R alpha 2 regulates the bioavailability of both IL-13 and IL-4 and is over-expressed in glioma and several bronchial pathologies (10, 15, 16). Compared to wild type IL-13, the atopy-associated R110Q variant of IL-13 elicits increased responsiveness from eosinophils that express low levels of IL-13 R alpha 2 (17).
Wills-Karp, M. (2004) Immunol. Rev. 202:175.
Nakajima H. and K. Takatsu (2007) Int. Arch. Allergy Immunol. 142:265.
McKenzie, A.N. et al. (1993) Proc. Natl. Acad. Sci. USA 90:3735.
Moy, F.J. et al. (2001) J. Mol. Biol. 310:219.
Eisenmesser, E.Z. et al. (2001) J. Mol. Biol. 310:231.
Ruetten, H. and C. Thiemermann (1997) Shock 8:409.
Lakkis, F.G. et al. (1997) Biochem. Biophys. Res. Commun. 235:529.
Wynn, T.A. (2003) Annu. Rev. Immunol. 21:425.
Andrews, A.L. et al. (2002) J. Biol. Chem. 277:46073.
Tabata, Y. et al. (2007) Curr. Allergy Asthma Rep. 7:338.
Chiaramonte, M.G. et al. (2003) J. Exp. Med. 197:687.
Daines, M.O. and G.K. Hershey (2002) J. Biol. Chem. 227:10387.
Matsumura, M. et al. (2007) Biochem. Biophys. Res. Commun. 360:464.
Tabata, Y. et al. (2007) J. Immunol. 177:7905.
Andrews, A.L. et al. (2006) J. Allergy Clin. Immunol. 118:858.
Joshi, B.H. et al. (2006) Vitam. Horm. 74:479.
Andrews, A-L. et al. (2007) J. Allergy Clin. Immunol. 120:91.
R&D Systems personnel manually curate a database that contains references using R&D Systems products.
The data collected includes not only links to publications in PubMed,
but also provides information about sample types, species, and experimental conditions.
Th2 cytokine response in Major Depressive Disorder patients before treatment.
Authors: Pavon L, Kiryushko D, Novitskaya V, Sandoval-Lopez G, Eugenia Hernandez M, Soroka V, Klingelhofer J, Loria F, Estrada I, Lukanidin E, Berezin V, Perez M, Moreno J, Bock E, Avila U, Leff P, Anton B, Heinze G
J. Neuroimmunol., 2006;172(1):156-65.
Sample Type: Serum
Application: ELISA Development
No product specific FAQs exist for this product, however you may
Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you
include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image.
Limited to verified customers in USA, Canada and Europe.
Read what people are saying who have used Human IL-13 Antibody.
We have 2 reviews tested in 2 species: Hamster, Human.
We have 2 reviews tested in 2 applications: ELISA, Immunocytochemistry/Immunofluorescence.